Penn Capital Management Co Inc buys $40,005,691 stake in Sagent Pharmaceuticals Inc (SGNT)

Sagent Pharmaceuticals Inc (SGNT) : Penn Capital Management Co Inc scooped up 107,048 additional shares in Sagent Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,841,035 shares of Sagent Pharmaceuticals Inc which is valued at $40,005,691.Sagent Pharmaceuticals Inc makes up approximately 2.21% of Penn Capital Management Co Inc’s portfolio.

Other Hedge Funds, Including , Kennedy Capital Management reduced its stake in SGNT by selling 14,330 shares or 3.03% in the most recent quarter. The Hedge Fund company now holds 458,943 shares of SGNT which is valued at $9,972,831. Sagent Pharmaceuticals Inc makes up approx 0.19% of Kennedy Capital Management’s portfolio.Tfs Capital reduced its stake in SGNT by selling 84,282 shares or 47.62% in the most recent quarter. The Hedge Fund company now holds 92,721 shares of SGNT which is valued at $2,014,827. Sagent Pharmaceuticals Inc makes up approx 0.35% of Tfs Capital’s portfolio. Tci Wealth Advisors sold out all of its stake in SGNT during the most recent quarter. The investment firm sold 79 shares of SGNT which is valued $1,716. Thompson Davis added SGNT to its portfolio by purchasing 250 company shares during the most recent quarter which is valued at $5,420. Sagent Pharmaceuticals Inc makes up approx 0.01% of Thompson Davis’s portfolio.California State Teachers Retirement System boosted its stake in SGNT in the latest quarter, The investment management firm added 6,597 additional shares and now holds a total of 53,912 shares of Sagent Pharmaceuticals Inc which is valued at $1,170,430.

Sagent Pharmaceuticals Inc opened for trading at $21.74 and hit $21.76 on the upside on Monday, eventually ending the session at $21.76, with a gain of 0.14% or 0.03 points. The heightened volatility saw the trading volume jump to 2,60,421 shares. Company has a market cap of $716 M.

On the company’s financial health, Sagent Pharmaceuticals Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.00. The company had revenue of $67.80 million for the quarter, compared to analysts expectations of $74.22 million. The company’s revenue was down -17.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.04 EPS.

Many Wall Street Analysts have commented on Sagent Pharmaceuticals Inc. Sagent Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 11, 2016. Sagent Pharmaceuticals Inc was Downgraded by Raymond James to ” Mkt Perform” on Jul 11, 2016.

Sagent Pharmaceuticals Inc. (Sagent) formerly Sagent Holding Co. is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective oncolytic and critical care indications in a variety of presentations including single- and multi-dose vials pre-filled ready-to-use syringes medical devices and premix bags. As of October 31 2010 Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides) which is an Indian manufacturer of finished pharmaceutical products.

Leave a Reply

Sagent Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sagent Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.